Invex Therapeutics Ltd (ASX:IXC)
Australia
· Delayed Price · Currency is AUD
0.110
0.00 (0.00%)
Mar 9, 2026, 3:03 PM AEST
Invex Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
| TTM
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| Other Revenue | 0.23 | 0.23 | 1.21 | 0.46 | 0.18 | - | |
| Revenue | 0.23 | 0.23 | 1.21 | 0.46 | 0.18 | - | |
| Revenue Growth (YoY) | -81.10% | -81.10% | 164.06% | 151.90% | - | - | |
| Gross Profit | 0.23 | 0.23 | 1.21 | 0.46 | 0.18 | - | |
| Selling, General & Admin | 1.07 | 0.72 | 1.17 | 1.12 | 0.9 | 0.74 | |
| Research & Development | 0.24 | 0.2 | 2.04 | 7.4 | 2.96 | 1.14 | |
| Operating Expenses | 1.31 | 0.94 | 3.35 | 9.01 | 4.22 | 2.44 | |
| Operating Income | -1.08 | -0.71 | -2.13 | -8.55 | -4.03 | -2.44 | |
| Interest & Investment Income | 0.18 | 0.23 | 0.49 | 0.8 | 0.08 | 0.16 | |
| Other Non Operating Income (Expenses) | 0.06 | - | - | - | - | 0 | |
| EBT Excluding Unusual Items | -0.84 | -0.48 | -1.64 | -7.75 | -3.95 | -2.28 | |
| Pretax Income | -0.84 | -0.48 | -1.64 | -7.75 | -3.95 | -2.28 | |
| Net Income | -0.84 | -0.48 | -1.64 | -7.75 | -3.95 | -2.28 | |
| Net Income to Common | -0.84 | -0.48 | -1.64 | -7.75 | -3.95 | -2.28 | |
| Shares Outstanding (Basic) | 75 | 76 | 75 | 75 | 75 | 75 | |
| Shares Outstanding (Diluted) | 75 | 76 | 75 | 75 | 75 | 75 | |
| Shares Change (YoY) | -0.29% | 0.51% | 0.19% | 0.02% | 0.03% | 33.77% | |
| EPS (Basic) | -0.01 | -0.01 | -0.02 | -0.10 | -0.05 | -0.03 | |
| EPS (Diluted) | -0.01 | -0.01 | -0.02 | -0.10 | -0.05 | -0.03 | |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - | |
| Operating Margin | -471.50% | -309.63% | -176.00% | -1861.73% | -2212.89% | - | |
| Profit Margin | -364.90% | -208.16% | -135.43% | -1688.11% | -2169.06% | - | |
| EBIT | -1.08 | -0.71 | -2.13 | -8.55 | -4.03 | -2.44 | |
| EBIT Margin | - | - | -176.00% | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.